In immediate-release tablet manufacturing for urinary-tract antibacterial therapy, oxolinic acid pharma grade API is specified for dry granulation or roller compaction when the milled particle size D90 falls below 75 µm and tapped bulk density falls below 0.45 g/mL, because direct compression at an active substance fraction above 40 wt% tends to segregate during hopper discharge and produce weight variation outside 21 CFR 211.110(b) in-process boundaries. Release testing for oral solid dosage forms is anchored to USP <621> or Ph. Eur. 2.2.29 for assay, USP <905> and Ph. Eur. 2.9.40 for uniformity of dosage units, USP <711> and Ph. Eur. 2.9.3 for dissolution, USP <701> and Ph. Eur. 2.9.1 for disintegration, and USP <921> Method Ia for water content. Elemental impurities and residual solvents are controlled under ICH Q3D(R2) and ICH Q3C(R8). The formulation platform for a representative 250 mg immediate-release tablet core weighing 580–650 mg places the active substance at 38–43 wt%; a 750 mg core weighing 1,100–1,200 mg increases the active fraction to 62–68 wt%. General tablet formulation ranges are active substance 40–65 wt%, microcrystalline cellulose plus lactose monohydrate or mannitol 20–40 wt%, crospovidone or sodium starch glycolate 2–5 wt%, pregelatinized starch or copovidone binder 2–5 wt%, colloidal anhydrous silica 0.2–0.8 wt%, and magnesium stearate 0.5–1.5 wt%. Calcium phosphate dibasic, calcium carbonate, magnesium carbonate, and aluminum lake pigments are excluded because multivalent cations can chelate the quinolone active and reduce oral absorption; magnesium stearate is accepted only after dissolution compatibility screening because free-ion availability is lot-dependent. The manufacturing sequence uses a conical mill fitted with a 0.5–0.8 mm screen for API delumping, bin blending at 8–12 rpm for 15–25 min, roller compaction at roll gap 1.0–2.0 mm and roll force 4–10 kN/cm, ribbon milling through a 1.0–1.5 mm screen, and final lubrication for 3–5 min. Compression is performed on a 45-station rotary press operating at 45,000–80,000 tablets/h with compression force 8–20 kN and target hardness 8–12 kp. Production-scale campaigns have recorded increased punch-face sticking when tooling temperature exceeds 45°C; forced air cooling of the die table and punch-tip polishing are used for campaigns longer than 8 h. Terminal product types include immediate-release film-coated tablets in 100 mg, 250 mg, 500 mg, and 750 mg label claims where national marketing authorizations permit; packaging is typically cold-formed aluminum or PVC/PCTFE-Alu blister to limit moisture and photodegradation.

Why Does High-Shear Wet Granulation Precede Capsule Filling for Low-Density Oxolinic Acid Blends?

Capsule filling of oxolinic acid pharma grade API is selected when flexible dose titration across 100–500 mg hard-shell units is required for clinical or commercial supply. The powder blend for a size 0 capsule typically contains active substance at 20–50 wt%, lactose monohydrate or microcrystalline cellulose at 35–60 wt%, croscarmellose sodium or sodium starch glycolate at 2–4 wt%, copovidone or pregelatinized starch at 2–5 wt%, and magnesium stearate at 0.5–1.0 wt%. High-shear wet granulation is used because oxolinic acid powder with D90 below 75 µm frequently shows an angle of repose above 40° and a Hausner ratio above 1.40; these powder properties prevent consistent dosator filling at speeds above 30,000 capsules/h and cause weight variation failures under 21 CFR 211.110(b). The granulation process operates with impeller speed 150–300 rpm, chopper speed 1,500–3,000 rpm, and wet massing time 2–5 min; the wet mass is milled through a 1.5 mm screen and dried in a fluid-bed dryer with inlet air at 55–70°C and product temperature below 40°C until loss-on-drying reaches 1.5–3.0%. Dried granules are sized through a 0.8–1.0 mm screen, blended with extragranular disintegrant and lubricant, and filled on a dosator or tamping-pin encapsulation machine. Powder flow is characterized according to USP <1174> and Ph. Eur. 2.9.36; content uniformity is assessed with USP <905> and Ph. Eur. 2.9.40. Terminal product types include hard gelatin and HPMC capsules in sizes 0 and 1, with label strengths commonly 100 mg, 250 mg, and 500 mg where authorized; capsules are packaged in PVC/PCTFE-Alu blister for moisture protection.

Before sachet filling of oxolinic acid oral suspension granules, the formulation is wet-granulated rather than directly filled because the active substance tends to segregate in dry blends at contents below 15 wt% and the powder flow is insufficient for high-speed sachet machinery. The granule formulation for reconstitution contains the active substance at 5–20 wt%, sucrose or sorbitol at 45–70 wt%, microcrystalline cellulose and sodium carboxymethylcellulose as suspending agents at 1–3 wt%, povidone or hydroxypropyl cellulose as binder at 1–3 wt%, sodium benzoate or potassium sorbate as preservative at 0.1–0.2 wt%, and flavoring at 0.2–0.8 wt%. Aluminum lake pigments are excluded because aluminum cations can chelate the quinolone active; color-free or titanium dioxide-free formulations are preferred. Manufacture uses high-shear granulation with purified water as the granulating fluid, followed by fluid-bed drying at inlet air 55–70°C and product temperature below 40°C to a final water content below 2.0%. Dried granules are screened through a 0.8–1.25 mm sieve, blended for 15–20 min in a low-shear blender, and filled into trilaminate sachets under controlled relative humidity below 40%. Single-dose sachets comply with uniformity of mass under Ph. Eur. 2.9.5 and uniformity of dosage units under USP <905>; particle-size distribution is controlled by analytical sieving per Ph. Eur. 2.9.38 and USP <786>. Preservative effectiveness is verified under Ph. Eur. 5.1.3. Terminal product types include unit-dose sachets and bulk bottles with a measuring spoon or cup for reconstitution into an oral suspension; the reconstituted product is typically assigned a use period of 7–14 days when the preservative system meets acceptance criteria.

Sterile Filtration and pH-Controlled Compounding of Injectable Oxolinic Acid Sodium Solutions

In parenteral manufacturing, oxolinic acid is formulated as the sodium salt because the free acid exhibits pH-dependent aqueous solubility and does not remain in solution at neutral pH at concentrations suitable for intravenous or intramuscular administration. A sterile solution is compounded to contain the active substance equivalent to 5–20 mg/mL free acid, with sodium chloride or dextrose added to adjust osmolality to 270–330 mOsm/kg, and 0.1–0.5 N sodium hydroxide or hydrochloric acid for pH adjustment above the drug’s pKa, typically above pH 9.0. The solution is prepared in water for injection under nitrogen overlay; carbon dioxide ingress lowers pH and can precipitate the free acid. Compounding vessels are jacketed stainless steel with bottom-mounted magnetic stirrers; dissolution is carried out at 15–25°C with continuous nitrogen sparging. The solution is passed through a 0.45 µm prefilter and then a 0.22 µm PVDF or PES sterilizing-grade filter at a flow rate not exceeding the filter manufacturer’s validated limit. Aseptic processing under EU GMP Annex 1 is the default because published data for terminal steam sterilisation of oxolinic acid at F0 ≥ 8 min are limited; if terminal sterilisation is pursued, forced degradation data under Ph. Eur. 5.1.1 must demonstrate impurity control. Filling is performed in a Grade A environment with Grade B background using peristaltic or rotary piston pumps; Type I borosilicate glass vials are washed, depyrogenated at 250°C for not less than 30 min, and filled with a nitrogen headspace. Release tests include sterility per Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxins per Ph. Eur. 2.6.14 or USP <85>, particulate matter per Ph. Eur. 2.9.19 and USP <788>/USP <790>, osmolality per USP <785>, and pH per USP <791>. Container closure integrity is validated per USP <1207>; extractables and leachables are assessed per USP <1663> and USP <1664>. Silicone oil in vial stoppers or filling-tube surfaces should be evaluated because quinolone compounds may adsorb to hydrophobic surfaces at low concentrations; a filter compatibility and adsorption study at the target concentration is required before scale-up. Terminal product types include 2–20 mL single-dose Type I glass vials and ampoules; lyophilized powder for injection is used when solution storage stability is insufficient, with reconstitution diluent supplied separately.

When oxolinic acid is designated for aquaculture medicated feed premises in jurisdictions where such use remains approved, the premix is treated as a veterinary medicinal intermediate rather than a pharmaceutical dosage form. Premix concentrates commonly contain the active substance at 1–10 wt% on a feed-grade carrier; the final feed inclusion rate is derived from the approved dose per kilogram of fish biomass per day and the observed voluntary feed intake, often falling in the range of 0.05–0.5 wt% in the finished feed, although published data for specific oxolinic acid final feed ratios are limited and must be taken from national registration documents. Homogeneity and cross-contamination control are addressed under Regulation (EC) No 183/2005 on feed hygiene and Regulation (EU) 2019/6 on veterinary medicinal products; carry-over limits and withdrawal periods are species-specific and temperature-dependent, and are defined by the competent authority. The premix is prepared by dry blending the API through a 0.5 mm sieve with a feed-grade carrier such as soybean meal or lactose-free starch for 10–15 min, followed by intermediate dilution at a ratio of 1:10 to 1:100 before final feed mixing. Production-scale paddle or ribbon mixers achieve a coefficient of variation below 5% after the intermediate dilution step. Incorporation into extruded feed is performed by top-coating onto cooled pellets with fish oil or a binder solution, because published data on the thermal stability of oxolinic acid in extrusion barrel conditions above 90°C are limited; top-coating at 30–40°C avoids unnecessary thermal exposure. Terminal product types include medicated extruded pellets and top-coated feed granules for oral administration to finfish; discharged uneaten feed and fecal material require environmental assessment under local aquaculture regulations.